A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17
暂无分享,去创建一个
M. Netea | B. Strober | M. Lebwohl | P. Gisondi | A. Blauvelt | U. Mrowietz | R. Warren | J. Merola | R. Langley | M. Ståhle | A. Armstrong | Natalie Nunez Gomez
[1] R. Dellavalle,et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study , 2021, Frontiers in Medicine.
[2] B. Strober,et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. , 2021, The New England journal of medicine.
[3] Y. Lee,et al. Relative efficacy and safety of secukinumab and guselkumab for the treatment of active psoriatic arthritis: A network meta-analysis. , 2021, International journal of clinical pharmacology and therapeutics.
[4] D. Baeten,et al. IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong? , 2021, Frontiers in Immunology.
[5] K. Reich,et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial , 2021, The Lancet.
[6] K. Kridin,et al. 47th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) , 2021, Experimental dermatology.
[7] B. Elewski,et al. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review , 2020, American Journal of Clinical Dermatology.
[8] Michael P. Lee,et al. Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis. , 2020, Cutis.
[9] A. Lawson,et al. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F , 2020, Frontiers in Immunology.
[10] A. Armstrong,et al. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. , 2020, JAMA.
[11] Irah L. King,et al. Innate Lymphocytes in Psoriasis , 2020, Frontiers in Immunology.
[12] M. Jaeger,et al. Recurrent Vulvovaginal Candidiasis: An Immunological Perspective , 2020, Microorganisms.
[13] A. Sultan,et al. Oral Candidiasis: A Disease of Opportunity , 2020, Journal of fungi.
[14] S. Gaffen,et al. Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity , 2020, Science Immunology.
[15] U. Mrowietz,et al. Interleukin-17 cytokines: Effectors and targets in psoriasis—A breakthrough in understanding and treatment , 2019, The Journal of experimental medicine.
[16] A. Mohamed,et al. Diagnosis and Treatment of Esophageal Candidiasis: Current Updates , 2019, Canadian journal of gastroenterology & hepatology.
[17] M. Komine,et al. Risk Factors for the Development of Psoriasis , 2019, International journal of molecular sciences.
[18] T. Beikler,et al. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases , 2019, International journal of molecular sciences.
[19] C. Marek,et al. Candidiasis: Red and White Manifestations in the Oral Cavity , 2019, Head and Neck Pathology.
[20] M. Umeda,et al. A retrospective study of factors associated with the development of oral candidiasis in patients receiving radiotherapy for head and neck cancer , 2018, Medicine.
[21] D. Katzka,et al. Infections of the esophagus: an update on risk factors, diagnosis, and management. , 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[22] A. Blauvelt,et al. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis , 2018, Clinical Reviews in Allergy & Immunology.
[23] J. Roliński,et al. Prevalence and Possible Role of Candida Species in Patients with Psoriasis: A Systematic Review and Meta-Analysis , 2018, Mediators of inflammation.
[24] S. Tavakolpour,et al. Oral Candida colonization and plaque type psoriasis: Is there any relationship? , 2018, Journal of investigative and clinical dentistry.
[25] M. Umemura,et al. Interleukin‐17 family cytokines in protective immunity against infections: role of hematopoietic cell‐derived and non‐hematopoietic cell‐derived interleukin‐17s , 2018, Microbiology and immunology.
[26] B. Peters,et al. Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: “Neutrophil Anergy” , 2017, Infection and Immunity.
[27] D. Williams,et al. Diagnosis and management of oral candidosis , 2017, BDJ.
[28] S. Gaffen,et al. Innate Immunity to Mucosal Candida Infections , 2017, Journal of fungi.
[29] C. Zachariae,et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin‐17 inhibitors and their practical management , 2017, The British journal of dermatology.
[30] J. Kolls,et al. Interluekin-17A (IL17A). , 2017, Gene.
[31] M. Veldhoen. Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.
[32] L. Taams,et al. IL-17+ CD8+ T cells: Differentiation, phenotype and role in inflammatory disease , 2016, Immunology letters.
[33] M. Nguyen,et al. Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework , 2016, Infection and Immunity.
[34] G. Adams,et al. Oral candidal carriage in asymptomatic patients. , 2016, Australian dental journal.
[35] J. Sobel,et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] L. Joosten,et al. Immune defence against Candida fungal infections , 2015, Nature Reviews Immunology.
[37] A. Mantovani,et al. Interleukin-17 and innate immunity in infections and chronic inflammation. , 2015, Journal of autoimmunity.
[38] B. Soltész,et al. The Evolving View of IL-17-Mediated Immunity in Defense Against Mucocutaneous Candidiasis in Humans , 2015, International reviews of immunology.
[39] M. Lebwohl,et al. IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies , 2015, The Journal of investigative dermatology.
[40] J. Bagan,et al. Current treatment of oral candidiasis: A literature review , 2014, Journal of clinical and experimental dentistry.
[41] A. Puel,et al. IL-17 and infections. , 2014, Actas dermo-sifiliograficas.
[42] L. Skov,et al. Targeting of interleukin-17 in the treatment of psoriasis , 2014, Clinical, cosmetic and investigational dermatology.
[43] Y. Jiménez-Soriano,et al. Clinical and microbiological diagnosis of oral candidiasis , 2013, Journal of clinical and experimental dentistry.
[44] L. Patton,et al. Oral candidiasis: pathogenesis, clinical presentation, diagnosis and treatment strategies. , 2013, Journal of the California Dental Association.
[45] J. Casanova,et al. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis , 2012, Current opinion in allergy and clinical immunology.
[46] H. Kang,et al. Prevalence and Risk Factors of Esophageal Candidiasis in Healthy Individuals: A Single Center Experience in Korea , 2012, Yonsei medical journal.
[47] M. Al-Aboosi,et al. Oral Candida colonization and candidiasis in patients with psoriasis. , 2012, Oral surgery, oral medicine, oral pathology and oral radiology.
[48] P. Krishnan,et al. Fungal infections of the oral mucosa. , 2012, Indian journal of dental research : official publication of Indian Society for Dental Research.
[49] C. Bodemer,et al. Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity , 2011, Science.
[50] Yoichiro Iwakura,et al. Review Functional Specialization of Interleukin-17 Family Members , 2022 .
[51] K. Shetty,et al. Diagnosis and management of oral candidiasis. , 2011, Otolaryngologic clinics of North America.
[52] T. Young,et al. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. , 2010, The Cochrane database of systematic reviews.
[53] C. Farah,et al. Oral fungal infections: an update for the general practitioner. , 2010, Australian dental journal.
[54] A. Parolia,et al. Asthma and oral health: a review. , 2010, Australian dental journal.
[55] S. Gaffen,et al. Interleukin‐17 and its target genes: mechanisms of interleukin‐17 function in disease , 2010, Immunology.
[56] S. Way,et al. Interleukin‐17 in host defence against bacterial, mycobacterial and fungal pathogens , 2009, Immunology.
[57] Kathleen M. Smith,et al. Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.
[58] C. Fichtenbaum,et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] G. Slade,et al. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons , 2004, Infection and Immunity.
[60] J. Chave,et al. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled trial. , 2002, The Journal of antimicrobial chemotherapy.
[61] J. Malo,et al. Occurrence and risk factors of oral candidiasis treated with oral antifungals in seniors using inhaled steroids. , 2000, Journal of clinical epidemiology.
[62] S. Hilsenbeck,et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. , 1998, The American journal of medicine.
[63] W. El-Sadr,et al. Weekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection , 1997, Annals of Internal Medicine.
[64] D. Marriott,et al. Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV‐infected patients: A double‐blind placebo‐controlled study , 1993, The Medical journal of Australia.
[65] D. Stevens,et al. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. , 1991, Archives of internal medicine.
[66] E. Dunbar,et al. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. , 1990, The Journal of infection.
[67] P. Rompré,et al. Reassessing the presence of Candida albicans in denture-related stomatitis. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.